You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國中藥(00570.HK)2020年業績:營收148.06億,淨利16.63億元,均創歷史新高
格隆匯 03-31 01:45

格隆匯 3 月 31日丨中國中藥(00570.HK)公佈,截至2020年12月31日止12個月,公司收入合計148.06億元人民幣,同比增長3.4%;毛利91.26億元,同比增長6.4%;經調整EBITDA31.18億元,同比增長3.8%;公司擁有人應占溢利16.63億元,同比增長4.7%;每股盈利33.03分。

報吿期內,集團的營業額約為人民幣148.06億元,比去年同期上升3.4%,主要受到上半年新冠肺炎疫情影響,業務增長有所放緩。其中,中藥配方顆粒業務貢獻營業額約人民幣100.13億元,佔總營業額的67.6%;成藥業務營業額約人民幣30.67億元,佔總營業額的20.7%;中藥飲片業務營業額約人民幣12.37億元,佔總營業額的8.4%;中醫藥大健康業務營業額約人民幣1.06億元,佔總營業額的0.7%;產地綜合業務營業額約人民幣3.83億元,佔總營業額的2.6%。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account